Keyword

pathological complete response

Description: This is the absence of detectable residual invasive cancer in examined tissue after treatment, commonly assessed following neoadjuvant therapy.

Primary topic: Breast Cancer Treatment Studies (33%)

OpenAlex ID: keywords/pathological-complete-response

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

2012 · P. van Hagen, M.C.C.M. Hulshof, et al. · New England Journal of Medicine · 5,532

PDF

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

2009 · Joel S. Parker, Michael Mullins, et al. · Journal of Clinical Oncology · 4,727

PDF

Pembrolizumab for Early Triple-Negative Breast Cancer

2020 · Peter Schmid, Javier Cortes, et al. · New England Journal of Medicine · 3,247

PDF

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

2008 · Cornelia Liedtke, Chafika Mazouni, et al. · Journal of Clinical Oncology · 2,892

PDF

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

2022 · Patrick M. Forde, Jonathan Spicer, et al. · New England Journal of Medicine · 2,801

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

2012 · Gunter von Minckwitz, Michael Untch, et al. · Journal of Clinical Oncology · 2,653

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

2011 · Luca Gianni, Tadeusz Pienkowski, et al. · The Lancet Oncology · 2,382

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

1998 · B Fisher, J Bryant, et al. · Journal of Clinical Oncology · 2,167

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

2017 · Carsten Denkert, Gunter von Minckwitz, et al. · The Lancet Oncology · 2,151

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

2007 · Lisa A. Carey, E. Claire Dees, et al. · Clinical Cancer Research · 2,087

Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data

2010 · Monique Maas, Patty J Nelemans, et al. · The Lancet Oncology · 1,951

Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy

2004 · Angelita Habr-Gama, Rodrigo Oliva Perez, et al. · Annals of Surgery · 1,897

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

2005 · Roman Rouzier, Charles M. Perou, et al. · Clinical Cancer Research · 1,892

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

1997 · B Fisher, A Brown, et al. · Journal of Clinical Oncology · 1,802

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

2008 · Priya Rastogi, Stewart J. Anderson, et al. · Journal of Clinical Oncology · 1,789

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

2009 · Carsten Denkert, Sibylle Loibl, et al. · Journal of Clinical Oncology · 1,762

Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

2007 · W. Fraser Symmans, Florentia Peintinger, et al. · Journal of Clinical Oncology · 1,656

PDF

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

2022 · Andrea Cercek, Melissa Lumish, et al. · New England Journal of Medicine · 1,635

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

2016 · Brian D. Lehmann, Bojana Jovanović, et al. · PLoS ONE · 1,434

PDF

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

2020 · Myriam Chalabi, Lorenzo F. Fanchi, et al. · Nature Medicine · 1,406

Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

1999 · Henry M. Kuerer, Lisa A. Newman, et al. · Journal of Clinical Oncology · 1,332

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

2012 · José Baselga, Ian Bradbury, et al. · The Lancet · 1,318

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

2013 · A. Schneeweiss, S. Chia, et al. · Annals of Oncology · 1,268

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

2022 · Peter Schmid, Javier Cortes, et al. · New England Journal of Medicine · 1,264

PDF

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

2005 · Aman U. Buzdar, Nuhad K. Ibrahim, et al. · Journal of Clinical Oncology · 1,173

Works count: 28,270

Citation count: 487,900